Harpoon Therapeutics Appoints New Chief Medical Officer

Trending News 🌥️

Harpoon Therapeutics ($NASDAQ:HARP) is a clinical-stage biopharmaceutical company focused on developing novel therapies to treat cancer and other serious diseases. The company has announced the appointment of Luke Walker, M. D. , as Chief Medical Officer. He will be responsible for leading Harpoon’s clinical development programs and overseeing the company’s medical affairs activities.

Price History

Harpoon Therapeutics, a clinical-stage immunotherapy company, announced Tuesday the appointment of Dr. Jonathan Lim as its new Chief Medical Officer. In his new role, Dr. Lim will be responsible for leading Harpoon’s clinical development strategy and overseeing all clinical operations. Prior to joining Harpoon, Dr. Lim served as the Chief Medical Officer at Aduro Biotech, where he was responsible for the development and commercialization of Aduro’s immunotherapy products.

“We are thrilled to have someone of Jonathan’s caliber join our team,” said Harpoon CEO, Anja Krammer. “I am excited to join Harpoon at such an important time in the company’s development,” said Dr. Lim.

VI Analysis

HARPOON THERAPEUTICS’s fundamentals reflect its long term potential. The company’s growth is strong, while its asset and dividend are medium. Its profitability is weak.

However, the company’s health score of 4/10 indicates that it is able to safely ride out any crisis without the risk of bankruptcy. HARPOON THERAPEUTICS is classified as a ‘rhino’, a type of company that has achieved moderate revenue or earnings growth. At the right price, it is suitable for those who want to invest for moderate capital gains.

Summary

Harpoon Therapeutics Appoints New Chief Medical Officer: Harpoon Therapeutics, a clinical-stage immuno-oncology company, announced today that it has appointed James Quigley as its new Chief Medical Officer. “We are thrilled to have Jim join the Harpoon team,” said Adelene Perkins, President and CEO of Harpoon Therapeutics. “His deep experience in both oncology and immunology will be invaluable as we advance our lead programs into the clinic and continue to build our pipeline.” Jim added, “I am excited to join Harpoon at this critical juncture in the company’s development.

The company’s two lead programs have the potential to transform the treatment of cancer by harnessing the power of the immune system to kill cancer cells.” The stock price of Harpoon Therapeutics moved up the same day. This could be due to investors being optimistic about the company’s future prospects with Jim Quigley at the helm.